Dr.Taisheng Li’s Team Presents the “Chinese Solution” for HIV Immune Reconstitution Deficiency at CROI 2024

Dr.Taisheng Li’s Team Presents the “Chinese Solution” for HIV Immune Reconstitution Deficiency at CROI 2024

2024.03.29
At the 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024) held from March 3 to 6 in Denver, Colorado, USA, a study by Dr. Taisheng Li's team from the Peking Union Medical College Hospital was selected for a poster presentation and discussed at the fifth session. This conference, which started in 1993, has become one of the most influential meetings in the field of AIDS, attracting experts from around the world to share their latest research findings. The study presented by Dr. Li's team showcased a "Chinese solution" for addressing immune reconstitution deficiencies in HIV-infected individuals to the global academic community.
Dr. Shuihua Lu: First RCT Study Reported on a Novel Vaccine for Preventing Tuberculosis Relapse丨CROI Commentary

Dr. Shuihua Lu: First RCT Study Reported on a Novel Vaccine for Preventing Tuberculosis Relapse丨CROI Commentary

2024.03.29
Patients who have successfully completed tuberculosis treatment still face a high risk of relapse, making the development of vaccines to prevent recurrent pulmonary tuberculosis an important direction in TB prevention efforts. At the recently concluded 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024), a study presented as a late-breaking abstract (Abstract Number: 210) revealed that the novel tuberculosis vaccine H56:IC31, while not reducing the rate of TB relapse, enhanced both humoral and cellular immune responses in recipients. This marks the first clinical multicenter, randomized controlled trial (RCT) reported on the use of a TB vaccine for the prevention of relapse. The Infectious Disease Frontier has invited Dr. Shuihua Lu and his team from The Third People's Hospital of Shenzhen to introduce and comment on this study as follows.
Dr. Shuihua Lu: Trends in PAN-TB Treatment and Mid-term Report Review on QDB Study丨CROI Commentary

Dr. Shuihua Lu: Trends in PAN-TB Treatment and Mid-term Report Review on QDB Study丨CROI Commentary

2024.03.29
In recent years, the concept of PAN-TB treatment, representing a comprehensive approach to tuberculosis (TB) therapy, has seen numerous developmental breakthroughs. This universal treatment method is applicable to all types of TB patients and is not limited by the resistance of traditional anti-tuberculosis drugs (i.e., there's no need to test for drug resistance), offering advantages such as simplified treatment and shortened course duration. At the recently concluded 31st Conference on Retroviruses and Opportunistic Infections (CROI 2024), a Phase 2b/c study (Abstract No: 163) presented in the form of a late-breaking abstract was selected for oral presentation. This study explored the efficacy and safety of a 4-month regimen of Quabodepistat, Delamanid, and Bedaquiline in treating pulmonary TB. Infectious Disease Frontier has invited Dr.
Dr. Hui Wang: Long-acting Cabotegravir Maintains High Efficacy in Preventing HIV Among Populations with High Incidence of Bacterial STIs丨CROI Commentary

Dr. Hui Wang: Long-acting Cabotegravir Maintains High Efficacy in Preventing HIV Among Populations with High Incidence of Bacterial STIs丨CROI Commentary

2024.03.28
The association between sexually transmitted infections (STIs) and HIV infection has always been a focal point in the medical community. With the promotion of pre-exposure prophylaxis (PrEP) strategies to prevent HIV infection, the impact of STIs on the effectiveness of PrEP has become an urgent issue to address. At the recently concluded Conference on Retroviruses and Opportunistic Infections (CROI 2024), researchers presented an oral abstract (Abstract 131) that explored the relationship between STI status and the effectiveness of two PrEP regimens (CAB-LA and daily oral TDF/FTC). Infectious Disease Frontier invited Dr. Hui Wang from The Third People's Hospital of Shenzhen to provide an in-depth commentary on this study.
Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma

Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma

2024.03.28
Professor Haiwen Huang from The First Affiliated Hospital of Soochow University provided an enlightening discourse on the significant strides made in CAR T cell therapies, with a special emphasis on their pioneering work in FcRH5 CAR-T cells for multiple myeloma. The study not only showcased the remarkable journey of hematology research over the years but also spotlighted the transformative potential of next-generation CAR T cell therapies in offering new hope to patients with hematologic cancers.
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study

Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study

2024.03.27
In the evolving landscape of hematology and oncology, innovative treatments for challenging conditions like relapsed or refractory marginal zone lymphoma are of paramount importance. It is in this context that the recent phase 2, multicenter, open-label study investigating the efficacy of Orelabrutinib comes to light, marking a significant advancement in the therapeutic domain. This study, meticulously carried out by a dedicated team of researchers led by Professor Haiwen Huang from The First Affiliated Hospital of Soochow University, alongside esteemed colleagues from various prestigious institutions across China, has been a beacon of hope for patients grappling with this relentless malignancy. The findings of this groundbreaking research were meticulously documented in the American Journal of Hematology, underscoring not only the potential of Orelabrutinib as a viable treatment option but also the collaborative effort and expertise that epitomizes the spirit of innovation in the field. This endeavor, emblematic of the strides being made in hematology research, was brilliantly showcased during a session at the renowned Beijing Hematologic Tumor and Immunology Summit Forum, an event that has become a cornerstone for the dissemination of cutting-edge scientific knowledge and clinical practices.